Search results
Results from the WOW.Com Content Network
Stuck in a trading range, Allergan (NYSE: AGN) needs to win back investors as the company continues to look for new drug products to drive sales growth. Confidence is so bad that activist AGN ...
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.
For premium support please call: 800-290-4726 more ways to reach us
Stock name Symbol Country of origin A. O. Smith Corporation: AOS: US A10 Networks, Inc. ATEN: US AAC Holdings Inc. AAC: US AAR Corporation: AIR: US Aaron's Inc.
Allergan, Inc. was an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention and urologics. Allergan, Inc. was formed in 1948, incorporated in 1950 and became a public company in 1970. [ 2 ]
Allergan stock is worth a second look. Allergan’s sale of Teva stock is unfortunately timed because of Teva’s drop from the $30 range since selling its generics unit.
Since releasing its fourth-quarter results on Feb. 5, Allergan's share price is up 9.6%. This comfortably beats the S&P 500's return over the same time period, with the wider index being up 5.3%.